Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIPU study of nivolumab + ipilimumab with or without UV1 vaccine in malignant pleural mesothelioma
2019-002721-30Phase 2Active
- Sponsor
- Oslo University Hospital
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pleural mesothelioma comparing Nivolumab + ipilimumab with Nivolumab + ipilimumab + UV1 vaccine + sargramostim (2 arms). Primary endpoint: Progression-free survival. Started Jun 2020; status: active.
02
Drugs
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2019-002721-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002721-30.